HK1244493A1 - 使用凝固因子和多特異性抗體的聯合治療 - Google Patents
使用凝固因子和多特異性抗體的聯合治療Info
- Publication number
- HK1244493A1 HK1244493A1 HK18103925.4A HK18103925A HK1244493A1 HK 1244493 A1 HK1244493 A1 HK 1244493A1 HK 18103925 A HK18103925 A HK 18103925A HK 1244493 A1 HK1244493 A1 HK 1244493A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- combination therapy
- multispecific antibodies
- coagulation factors
- coagulation
- factors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15164045 | 2015-04-17 | ||
PCT/EP2016/057662 WO2016166014A1 (en) | 2015-04-17 | 2016-04-07 | Combination therapy with coagulation factors and multispecific antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1244493A1 true HK1244493A1 (zh) | 2018-08-10 |
Family
ID=52997894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18103925.4A HK1244493A1 (zh) | 2015-04-17 | 2018-03-21 | 使用凝固因子和多特異性抗體的聯合治療 |
Country Status (13)
Country | Link |
---|---|
US (3) | US20180244798A1 (zh) |
EP (1) | EP3283099B1 (zh) |
JP (1) | JP6698102B2 (zh) |
KR (1) | KR102057767B1 (zh) |
CN (1) | CN107454906B (zh) |
AR (1) | AR104280A1 (zh) |
AU (1) | AU2016248817A1 (zh) |
BR (1) | BR112017016952A2 (zh) |
CA (1) | CA2978038A1 (zh) |
HK (1) | HK1244493A1 (zh) |
IL (1) | IL253658A0 (zh) |
MX (1) | MX2017010734A (zh) |
WO (1) | WO2016166014A1 (zh) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
SI2202245T1 (sl) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR |
EP3050896B1 (en) | 2013-09-27 | 2021-07-07 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體 |
TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定fviii的反應性之方法 |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
MX2018007781A (es) | 2015-12-28 | 2018-09-05 | Chugai Pharmaceutical Co Ltd | Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc). |
MX2019002510A (es) | 2016-09-06 | 2019-06-24 | Chugai Pharmaceutical Co Ltd | Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado. |
US20230192896A1 (en) * | 2016-11-23 | 2023-06-22 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
MX2019009106A (es) * | 2017-02-01 | 2019-09-10 | Novo Nordisk As | Anticuerpos procoagulantes. |
CN110461358A (zh) * | 2017-03-31 | 2019-11-15 | 公立大学法人奈良县立医科大学 | 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物 |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
SG11201810270SA (en) | 2017-09-29 | 2019-04-29 | Chugai Pharmaceutical Co Ltd | Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing |
WO2019096874A1 (en) | 2017-11-15 | 2019-05-23 | Novo Nordisk A/S | Factor x binders enhancing fx activation |
FR3082427B1 (fr) * | 2018-06-14 | 2020-09-25 | Lab Francais Du Fractionnement | Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x |
BR112021000823A2 (pt) * | 2018-08-01 | 2021-04-13 | Novo Nordisk A/S | Anticorpo multiespecífico ou seu fragmento de ligação a antígeno. |
US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
WO2020114614A1 (en) * | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Proteinaceous molecules binding factor ixa and factor x |
WO2020114615A1 (en) * | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Bispecific antibodies binding factor ixa and factor x |
WO2020115281A1 (en) * | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Proteinaceous molecules binding factor ixa and factor x |
WO2020115283A1 (en) * | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Bispecific antibodies binding factor ixa and factor x |
PT3723858T (pt) | 2018-12-21 | 2022-02-02 | Kymab Ltd | Anticorpo biespecífico fixaxfx com cadeia leve comum |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614500A (en) | 1983-03-04 | 1997-03-25 | The Scripps Research Institute | Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
ES2153483T3 (es) * | 1994-07-11 | 2001-03-01 | Univ Texas | Metodos y composiciones para la coagulacion especifica en los vasos tumorales. |
ATE340590T1 (de) | 1994-07-13 | 2006-10-15 | Chugai Pharmaceutical Co Ltd | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DK1069185T3 (da) | 1998-04-03 | 2011-06-27 | Chugai Pharmaceutical Co Ltd | Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof |
EP2149604A1 (en) | 2000-09-08 | 2010-02-03 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
CA2465004A1 (en) * | 2003-05-19 | 2004-11-19 | National Institute For Biological Standards And Control | Composition |
WO2005035753A1 (ja) * | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
DE602005024955D1 (de) * | 2004-03-19 | 2011-01-05 | Baxter Healthcare Sa | Faktor ixa zur behandlung von blutungsstörungen |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
EP1876236B9 (en) | 2005-04-08 | 2015-02-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
WO2007101681A1 (en) | 2006-03-07 | 2007-09-13 | Baxter International Inc | Highly phosphorylated and sulfated recombinant factor ix |
EP1935429A1 (en) | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates |
KR101398363B1 (ko) * | 2010-11-17 | 2014-05-22 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
-
2016
- 2016-04-07 KR KR1020177029835A patent/KR102057767B1/ko active IP Right Grant
- 2016-04-07 WO PCT/EP2016/057662 patent/WO2016166014A1/en active Application Filing
- 2016-04-07 JP JP2017554448A patent/JP6698102B2/ja active Active
- 2016-04-07 CA CA2978038A patent/CA2978038A1/en not_active Abandoned
- 2016-04-07 AU AU2016248817A patent/AU2016248817A1/en not_active Abandoned
- 2016-04-07 EP EP16718244.3A patent/EP3283099B1/en active Active
- 2016-04-07 MX MX2017010734A patent/MX2017010734A/es unknown
- 2016-04-07 BR BR112017016952-5A patent/BR112017016952A2/pt not_active IP Right Cessation
- 2016-04-07 CN CN201680021103.3A patent/CN107454906B/zh active Active
- 2016-04-15 AR ARP160101027A patent/AR104280A1/es unknown
-
2017
- 2017-07-25 IL IL253658A patent/IL253658A0/en unknown
- 2017-10-16 US US15/784,478 patent/US20180244798A1/en not_active Abandoned
-
2018
- 2018-03-21 HK HK18103925.4A patent/HK1244493A1/zh unknown
-
2021
- 2021-04-20 US US17/235,198 patent/US20220119550A1/en not_active Abandoned
-
2023
- 2023-12-07 US US18/533,056 patent/US20240239917A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN107454906B (zh) | 2022-05-27 |
WO2016166014A1 (en) | 2016-10-20 |
EP3283099A1 (en) | 2018-02-21 |
JP2018513163A (ja) | 2018-05-24 |
AR104280A1 (es) | 2017-07-12 |
US20220119550A1 (en) | 2022-04-21 |
IL253658A0 (en) | 2017-09-28 |
KR20170125977A (ko) | 2017-11-15 |
EP3283099B1 (en) | 2022-03-02 |
JP6698102B2 (ja) | 2020-05-27 |
AU2016248817A1 (en) | 2017-08-17 |
US20180244798A1 (en) | 2018-08-30 |
US20240239917A1 (en) | 2024-07-18 |
CN107454906A (zh) | 2017-12-08 |
BR112017016952A2 (pt) | 2018-04-03 |
MX2017010734A (es) | 2017-12-04 |
CA2978038A1 (en) | 2016-10-20 |
KR102057767B1 (ko) | 2019-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244493A1 (zh) | 使用凝固因子和多特異性抗體的聯合治療 | |
HUS2400014I1 (hu) | Terápiás ellenanyagok és alkalmazásaik | |
IL261395A (en) | Combined treatment with antibodies against cd73 | |
IL258931A (en) | Medicinal compounds and methods | |
HK1232140A1 (zh) | 微類器官以及製造和使用它們的方法 | |
ZA201701491B (en) | Methods and therapeutic combinations for treating tumors | |
GB201519858D0 (en) | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof | |
IL259570A (en) | Combined therapy and their uses and methods | |
EP3334429C0 (en) | HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR | |
LT3341027T (lt) | Transfekcijos kompleksai ir jų panaudojimo būdai | |
GB201404470D0 (en) | Therapeutic methods and materials | |
HK1247091A1 (zh) | 治療抗體及其用途 | |
GB201511382D0 (en) | Novel compounds and their use in therapy | |
HK1258470A1 (zh) | 血液製備和圖譜分析 | |
IL250507B (en) | Anti-ck8 antibodies for use in cancer treatment | |
IL247325A0 (en) | Therapeutic methods using noribogaine and related compounds | |
HK1251171A1 (zh) | 腫瘤生物標誌物及其應用 | |
HK1249866A1 (zh) | 用他塞利昔布進行治療的方法 | |
GB201510461D0 (en) | New polymers and methods | |
IL249129A0 (en) | Tube and kit for resection with an inserted part | |
GB201401806D0 (en) | Novel methods for diagnosis and therapy | |
GB201501202D0 (en) | Novel methods for diagnosis and therapy | |
GB201509908D0 (en) | Methods and kits | |
GB201515440D0 (en) | Theraputic and diagnostic target | |
GB201515441D0 (en) | Theraputic and diagnostic target |